FrancophonIA/ELRC3.0 huggingface dataset:
English: During the long-term study, no bleeding episodes were observed in children below 6 years of age treated with NovoThirteen.
Slovenian: Med dolgoročno študijo niso opazili nobenih krvavitev pri otrocih, mlajših od šest let, zdravljenih z zdravilom NovoThirteen.
English: The safety and effectiveness of NovoThirteen in children below 6 years of age was supported by preliminary data from an ongoing long-term study during which the patients were given NovoThirteen to prevent bleeding episodes.
Slovenian: Varnost in učinkovitost zdravila NovoThirteen pri otrocih, mlajših od šest let, sta bili podprti s predhodnimi podatki iz potekajoče dolgoročne študije, med katero so bolniki to zdravilo prejemali za preprečevanje krvavitev.
English: This includes information on storage procedures, since incorrect storage after reconstitution can cause increased levels of activated NovoThirteen, thereby increasing the risk of thrombosis (formation of blood clots in the blood vessels), and information on administration procedures, since the factor XIII concentration in NovoThirteen is different from other factor XIIIcontaining medicines.
Slovenian: Vsebovale bodo informacije o postopkih shranjevanja, saj lahko nepravilno shranjevanje po pripravi povzroči povišane ravni aktiviranega zdravila NovoThirteen in s tem poveča tveganje za trombozo (tvorjenje krvnih strdkov v ožilju), ter informacije o načinih uporabe, saj je koncentracija faktorja XIII v zdravilu NovoThirteen drugačna kot pri drugih zdravilih, ki ga vsebujejo.
English: The patients were given NovoThirteen for one year for preventative use.
Slovenian: Bolniki so eno leto preventivno prejemali zdravilo NovoThirteen.
English: A specific component of factor XIII called the A-subunit is involved in stabilising blood clots and increasing the strength of the clot.
Slovenian: Posebna sestavina faktorja XIII, imenovana podenota A, sodeluje pri stabilizaciji krvnih strdkov in povečevanju njihove trdnosti.
English: NovoThirteen's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor je zato zaključil, da so koristi zdravila NovoThirteen večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: What is the risk associated with NovoThirteen?
Slovenian: Kakšna tveganja so povezana z zdravilom NovoThirteen?
English: NovoThirteen was investigated in a main study involving 41 adults and children above 6 years of age with congenital factor XIII A-subunit deficiency who had been treated in the past with medicines containing factor XIII.
Slovenian: Zdravilo NovoThirteen so proučevali v glavni študiji, v katero je bilo vključenih 41 odraslih in otrok, starejših od šest let, s prirojenim pomanjkanjem podenote A faktorja XIII, ki so se v preteklosti zdravili z zdravili, ki vsebujejo faktor XIII.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for NovoThirteen, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila NovoThirteen in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: The factor XIII A-subunit in NovoThirteen is made by a method known as ‘recombinant DNA technology': it is produced by yeast cells that have received the gene (DNA) which makes the cells able to produce it.
Slovenian: Podenoto A faktorja XIII v zdravilu NovoThirteen proizvajajo z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri kvasovke prejmejo gen (DNK), s katerimi jo lahko tvorijo.
English: Patients with congenital factor XIII A-subunit deficiency do not have enough of the factor XIII A-subunit, or it does not work correctly, which makes them prone to bleeding.
Slovenian: Bolniki s prirojenim pomanjkanjem podenote A faktorja XIII imajo te enote premalo ali jim ne deluje pravilno, zaradi česar so nagnjeni h krvavitvam.
English: NovoThirteen works by providing the factor XIII A-subunit, which helps to prevent bleeding in these patients.
Slovenian: Zdravilo NovoThirteen deluje tako, da zagotavlja podenoto A faktorja XIII, kar pomaga pri preprečevanju krvavitev pri teh bolnikih.
English: The active substance in NovoThirteen, catridecacog, is structurally the same as the human factor XIII A-subunit.
Slovenian: Zdravilna učinkovina zdravila NovoThirteen, katridekakog, je po zgradbi enaka človeški podenoti A faktorja XIII.
English: The study looked at the number of bleeding episodes requiring treatment with a factor XIII-containing medicine in these patients, compared with patients who had not received NovoThirteen, based on earlier data from 16 patients with congenital factor XIII A-subunit deficiency.
Slovenian: V študiji so proučevali število krvavitev, pri katerih je bilo pri teh bolnikih potrebno zdravljenje z zdravilom, ki vsebuje faktor XIII, v primerjavi z bolniki, ki niso prejemali zdravila NovoThirteen, na podlagi predhodnih podatkov 16 bolnikov s prirojenim pomanjkanjem podenote A faktorja XIII.
English: Why has NovoThirteen been approved?
Slovenian: Zakaj je bilo zdravilo NovoThirteen odobreno?
English: NovoThirteen does not work in patients lacking the factor XIII B-subunit.
Slovenian: Zdravilo ne deluje pri bolnikih, ki jim primanjkuje podenota B faktorja XIII.
English: The rate of bleeding episodes in patients receiving NovoThirteen preventatively was lower than the rate seen in the earlier data from patients treated on demand with another medicine containing factor XIII.
Slovenian: Pri bolnikih, ki so zdravilo NovoThirteen prejemali preventivno, je bila pogostost krvavitev manjša od pogostosti, razvidne iz predhodnih podatkov bolnikov, zdravljenih po potrebi z drugim zdravilom, ki vsebuje faktor XIII.
English: NovoThirteen is used for the long-term prevention of bleeding in patients with a condition called ‘congenital factor XIII A-subunit deficiency'.
Slovenian: Zdravilo NovoThirteen se uporablja za dolgoročno preprečevanje krvavitev pri bolnikih z motnjo, imenovano prirojeno pomanjkanje podenote A faktorja XIII.
English: On average, there were approximately 0.15 bleeding episodes requiring factor XIII treatment per year per patient treated preventatively with NovoThirteen.
Slovenian: V povprečju je pri bolniku, preventivno zdravljenem z zdravilom NovoThirteen, na leto prišlo do približno 0,15 krvavitve, pri kateri je bilo potrebno zdravljenje s faktorjem XIII.
English: In certain situations the doctor may decide to adjust the dose required to prevent bleeding, based on the patient's factor XIII levels in the blood.
Slovenian: V določenih primerih se lahko zdravnik na podlagi analize bolnikove ravni faktorja XIII v krvi odloči, da prilagodi odmerek, potreben za preprečevanje krvavitev.
English: Moreover, no major side effects were seen with long term use of NovoThirteen.
Slovenian: Poleg tega pri dolgoročnem zdravljenju z zdravilom NovoThirteen niso bili opaženi resnejši neželeni učinki.
English: How has NovoThirteen been studied?
Slovenian: Kako je bilo zdravilo NovoThirteen raziskano?
English: What is NovoThirteen?
Slovenian: Kaj je zdravilo NovoThirteen?
English: What is NovoThirteen used for?
Slovenian: Za kaj se zdravilo NovoThirteen uporablja?
English: How does NovoThirteen work?
Slovenian: Kako zdravilo NovoThirteen deluje?
English: How is NovoThirteen used?
Slovenian: Kako se zdravilo NovoThirteen uporablja?
English: This compared with around 2.9 episodes per year per patient treated on demand with another medicine containing factor XIII.
Slovenian: Pri bolniku, zdravljenem po potrebi z drugim zdravilom, ki vsebuje faktor XIII, pa je na leto prišlo do 2,9 krvavitve.
English: The name of the medicine was changed to Vantavo on 26 March 2010.
Slovenian: Ime zdravila je bilo 26. marca 2010 spremenjeno v Vantavo.
English: The recommended dose is one tablet once a week.
Slovenian: Priporočeni odmerek zdravila Vantavo je ena tableta enkrat na teden.
English: Other information about Vantavo:
Slovenian: Druge informacije o zdravilu Vantavo:
English: What measures are being taken to ensure the safe and effective use of Vantavo?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Vantavo?
English: The full EPAR for Vantavo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Vantavo je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This authorisation was based on the authorisation granted to Fosavance in 2005 (‘informed consent').
Slovenian: Ta odobritev je temeljila na dovoljenju za promet z zdravilom Fosavance, izdanemu leta 2005 (uporaba dokumentacije s soglasjem).
English: The patient must take the tablet with a full glass of water (but not mineral water), at least 30 minutes before any food, drink, or other medicines (including antacids, calcium supplements and vitamins).
Slovenian: Bolnica mora tableto zaužiti s polnim kozarcem vode (vendar ne mineralne), in sicer najmanj 30 minut pred zaužitjem hrane, pijače ali drugih zdravil (vključno z antacidi, dodatki kalcija in vitamini).
English: This document is a summary of the European Public Assessment Report (EPAR) for Vantavo.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Vantavo.
English: A risk management plan has been developed to ensure that Vantavo is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Vantavo je bil pripravljen načrt obvladovanja tveganj.
English: the day, which should be at least 30 minutes after taking the tablet.
Slovenian: prvega dnevnega obroka hrane, kar pa ne sme biti prej kot 30 minut po zaužitju tablete.
English: For more information about treatment with Vantavo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Vantavo preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: The CHMP decided that Vantavo's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Vantavo večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: The tablet should be swallowed whole and not crushed, chewed or allowed to dissolve in the mouth.
Slovenian: Bolnice morajo tableto pogoltniti celo in je ne smejo zdrobiti, žvečiti ali raztopiti v ustih.
English: Vitamin D3 is a nutrient that is found in some foods, but is also made in the skin through exposure to natural sunlight.
Slovenian: Vitamin D3 je hranilna snov, ki jo najdemo v nekaterih vrstah hrane, z izpostavljanjem naravni sončni svetlobi pa nastaja tudi v koži.
English: Since patients with osteoporosis may not get enough vitamin D3 through exposure to sunlight, it is included in Vantavo.
Slovenian: Ker bolniki z osteoporozo z izpostavljanjem sončni svetlobi morda ne dobijo dovolj vitamina D3, je ta vključen v zdravilo Vantavo.
English: What benefit has Vantavo shown during the studies?
Slovenian: Kakšne koristi je zdravilo Vantavo izkazalo med študijami?
English: Osteoporosis is more common in women after the menopause, when the levels of the female hormone oestrogen fall, since oestrogen helps to keep bones healthy.
Slovenian: Osteoporoza je pogostejša pri ženskah v obdobju po menopavzi, ko raven ženskega hormona estrogena, ki prispeva k ohranjanju zdravih kosti, upade.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vantavo.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vantavo, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: The European Commission granted a marketing authorisation valid throughout the EU for Alendronate Sodium And Colecalciferol, MSD on 16 October 2009.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Alendronate Sodium And Colecalciferol, MSD, veljavno po vsej Evropski uniji, izdala 16. oktobra 2009.
English: Because alendronic acid and vitamin D3 are already used separately in authorised medicines in the EU, the company presented data obtained in earlier studies and from the published literature from women who had been through the menopause and who were taking alendronic acid and vitamin D as separate tablets.
Slovenian: Ker se alendronska kislina in vitamin D3 ločeno že uporabljata v zdravilih, odobrenih v EU, je družba predložila podatke iz starejših študij ter iz objavljene literature o ženskah, ki so že prestale menopavzo in so jemale alendronsko kislino in vitamin D kot ločeni tableti.
English: What is the risk associated with Vantavo?
Slovenian: Kakšna tveganja so povezana z zdravilom Vantavo?
English: 1 Previously known as Alendronate Sodium And Colecalciferol, MSD.
Slovenian: 1 Prej znano kot Alendronate Sodium and Colecalciferol, MSD.
English: Vitamin D3, along with other forms of vitamin D, is required for calcium absorption and normal bone formation.
Slovenian: Skupaj z drugimi vrstami vitamina D je potreben za absorpcijo kalcija in normalno tvorbo kostne mase.
English: It is available as tablets (70 mg alendronic acid and 2,800 international units [IU] colecalciferol; 70 mg alendronic acid and 5,600 IU colecalciferol).
Slovenian: Na voljo je v obliki tablet (70 mg alendronske kisline in 2 800 mednarodnih enot [i.e.] holekalciferola; 70 mg alendronske kisline in 5 600 i.e. holekalciferola).
English: The information presented by the company from earlier studies and the published literature showed that the dose of alendronic acid included in Vantavo was the same as the dose needed to prevent bone loss.
Slovenian: Podatki iz starejših študij in objavljene literature, ki jih je predstavila družba, so pokazali, da je odmerek alendronske kisline v zdravilu Vantavo enak odmerku, ki je potreben za preprečevanje izgube kostne mase.
English: For the full list of all side effects reported with Vantavo, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Vantavo, glejte navodilo za uporabo.
English: Why has Vantavo been approved?
Slovenian: Zakaj je bilo zdravilo Vantavo odobreno?
English: Vantavo must not be used in patients who have abnormalities of the oesophagus, who have hypocalcaemia (low blood calcium levels), or who cannot stand or sit upright for at least 30 minutes.
Slovenian: Zdravila Vantavo ne smejo uporabljati bolnice z nepravilnostmi v požiralniku, bolnice s hipokalciemijo (nizkimi ravnmi kalcija) ali tiste, ki vsaj 30 minut ne morejo vzravnano stati ali sedeti.
English: The most common side effects with Vantavo include abdominal pain (stomach ache), dyspepsia (heartburn), oesophageal (gullet) ulcers, dysphagia (difficulty swallowing), abdominal distension (swollen tummy) and acid regurgitation.
Slovenian: Najpogostejši neželeni učinki zdravila Vantavo so bolečine v trebuhu, dispepsija (zgaga), razjede požiralnika, disfagija (težave pri požiranju), napihnjen trebuh in refluks kisline.
English: This study was extended in 652 patients for a further 24 weeks to compare the effects of continuing with Vantavo 70 mg/2,800 IU on its own or adding 2,800 IU vitamin D3 (equivalent to using Vantavo 70 mg/5,600 IU).
Slovenian: Ta študija je bila pri 652 bolnikih podaljšana za nadaljnjih 24 tednov, da bi učinke nadaljevanja zdravljenja samo z zdravilom Vantavo 70 mg/2800 i.e. primerjali z učinki dodajanja 2800 i.e. vitamina D3 (kar je enakovredno uporabi zdravila Vantavo 70 mg/5600 i.e.).
English: To support the combination of alendronic acid and vitamin D3 in the same tablet, the company also carried out a study in 717 patients with osteoporosis, including 682 women who had been through the menopause, to show Vantavo's ability to increase vitamin D levels.
Slovenian: V podporo uporabi kombinacije alendronske kisline in vitamina D3 v isti tableti in za pridobitev dokazov, da zdravilo Vantavo lahko poveča ravni vitamina D, je družba izvedla študijo s 717 bolniki z osteoporozo, ki je vključevala 682 žensk, pri katerih se je že pojavila menopavza.
English: Vantavo is a medicine that contains two active substances: alendronic acid and colecalciferol (vitamin D3).
Slovenian: Vantavo je zdravilo, ki vsebuje dve zdravilni učinkovini: alendronsko kislino in holekalciferol (vitamin D3).
English: In the extension study, similar numbers of patients taking Vantavo 70 mg/2,800 IU and Vantavo 70 mg/5,600 IU had low vitamin D levels (below 6%), but the patients taking Vantavo 70 mg/5,600 IU had greater increases in vitamin D levels over the 24 weeks of the study.
Slovenian: V podaljšani študiji je bilo število bolnic z nizkimi ravnmi vitamina D (pod 6 %) v skupini, ki je jemala zdravilo Vantavo 70 mg/2 800 i.e. podobno številu bolnic v skupini, ki je prejemala zdravilo Vantavo 70 mg/5 600 i.e., vendar pa so se pri tistih, ki so jemale zdravilo Vantavo 70 mg/5 600 i.e., v 24 tednih študije ravni vitamina D bolj povečale.
English: Patients should also take calcium supplements if they are not getting enough calcium from their diet. For more information, see the package leaflet.
Slovenian: Bolnice morajo jemati tudi dodatke kalcija, če njegov vnos s prehrano ni zadosten.
English: Patients received either Vantavo 70 mg/2,800 IU or alendronic acid only once a week.
Slovenian: Bolnice so enkrat tedensko prejemale bodisi zdravilo Vantavo 70 mg/2 800 i.e. bodisi le alendronsko kislino.
English: What is Vantavo used for?
Slovenian: Za kaj se zdravilo Vantavo uporablja?
English: How has Vantavo been studied?
Slovenian: Kako je bilo zdravilo Vantavo raziskano?
English: Vantavo (containing either 2,800 or 5,600 IU colecalciferol) is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of low vitamin D levels.
Slovenian: Zdravilo Vantavo (ki vsebuje 2 800 ali 5 600 i.e. holekalciferola) se uporablja za zdravljenje osteoporoze (bolezni, ki povzroča krhkost kosti) pri ženskah po menopavzi, pri katerih obstaja tveganje za pomanjkanje vitamina D. Zdravilo Vantavo 70 mg/5 600 i.e. se uporablja pri bolnikih, ki ne jemljejo dodatkov vitamina D. Zdravilo zmanjšuje tveganje za zlome kosti v hrbtenici in kolkih.
English: Vantavo contains two active substances: alendronic acid and colecalciferol (vitamin D3).
Slovenian: Zdravilo Vantavo vsebuje dve zdravilni učinkovini: alendronsko kislino in holekalciferol (vitamin D3).
English: Vantavo alendronic acid and colecalciferol
Slovenian: Vantavo alendronska kislina in holekalciferol
English: How is Vantavo used?
Slovenian: Kako se zdravilo Vantavo uporablja?
English: What is Vantavo?
Slovenian: Kaj je zdravilo Vantavo?
English: How does Vantavo work?
Slovenian: Kako zdravilo Vantavo deluje?
English: After 15 weeks, fewer patients had low vitamin D levels when they took Vantavo 70 mg/2,800 IU (11%) than when they took alendronic acid only (32%).
Slovenian: Dodatne študije so pokazale, da lahko vključitev vitamina D3 in alendronske kisline v isto tableto poveča ravni vitamina D. Po 15 tednih zdravljenja je bil delež bolnic z nizko ravnjo vitamina D med bolniki, zdravljenih z zdravilom Vantavo 70 mg/2 800 i.e., nižji (11 %) kot pri tistih, ki so prejemale le alendronsko kislino (32 %).
English: Strength Pharmaceutical
Slovenian: Jakost Farmacevtska
English: EU Number Invented
Slovenian: EU številka
English: Packaging
Slovenian: Ciljna
English: 9 July 2001
Slovenian: 9. julij 2001
English: See the Module ”All authorised presentations”
Slovenian: Glej modul »All authorised presentations«
English: Levviax is indicated for the treatment of the following infections:
Slovenian: Levviax je indiciran za zdravljenje naslednjih okužb:
English: Date of issue of Marketing Authorisation valid throughout the European Union:
Slovenian: Datum izdaje dovoljenja za promet z zdravilom, veljavnega po vsej Evropski uniji:
English: For detailed conditions for the use of this product, scientific information or procedural aspects please refer to the relevant modules.
Slovenian: Podrobnosti o pogojih uporabe tega zdravila, informacijah znanstvene narave ter postopkovnih vidikih najdete v ustreznih modulih.
English: Pharmaco-therapeutic group (ATC Code):
Slovenian: Farmakološko-terapevtska skupina (ATC klasifikacija):
English: Telithromycin
Slovenian: telitromicin
English: LEVVIAX International Nonproprietary Name (INN): Telithromycin Abstract
Slovenian: Mednarodno nelastniško ime (INN): telitromicin
English: Currently approved therapeutic indication(s):
Slovenian: Trenutno odobrena(e) terapevtska(e) indikacija(e):
English: EMEA/H/C/0355 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR)
Slovenian: ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EUROPEAN PUBLIC ASSESSMENT REPORT - EPAR)
English: When prescribing Levviax, consideration should be given to official guidance on the appropriate use of antibacterial agents.
Slovenian: Pri predpisovanju zdravila Levviax je potrebno upoštevati uradne smernice za ustrezno uporabo protibakterijskih zdravil.
English: The initial approval was based on studies, which showed that the potential benefits with telithromycin particularly relate to its use in the treatment of infections caused by penicillin and/or erythromycin resistant S. pneumoniae.
Slovenian: Prvotna odobritev zdravila je temeljila na rezultatih študij, ki so pokazale, da so potencialne prednosti telitromicina povezane zlasti z njegovo uporabo pri zdravljenju okužb, povzročenih s S. pneumoniae, odpornimi proti penicilinu in/ali eritromicinu.
English: Telithromycin interacts with the translation at the 23S ribosomal RNA level and some data also indicate that assembly of the 30S subunit may be impaired.
Slovenian: Telitromicin ovira ribosomsko translacijo na ravni 23S ribosomske RNA, določeni podatki pa kažejo tudi na to, da zmore zavreti nastanek podenote 30S.
English: The CHMP, on the basis of quality, safety and efficacy data submitted, considers that the benefit risk ratio for Levviax is favourable in the approved indication
Slovenian: Na podlagi predloženih podatkov o kakovosti, varnosti in učinkovitosti zdravila CHMP meni, da je zdravilo Levviax izkazalo ugodno razmerje med tveganji in koristmi za odobreno indikacijo.
English: Orphan medicinal product designation date:
Slovenian: Datum določitve zdravila kot zdravila sirote:
English: The most common side effects are, as for macrolides, mainly reported from the digestive and nervous systems, with diarrhoea, nausea, headache and dizziness.
Slovenian: Najpogostejši stranski učinki so, tako kot pri makrolidih, povezani s prebavnim traktom in živčnim sistemom ter vključujejo drisko, navzeo, glavobol in vrtoglavico.
English: However, clinical experience is still rather limited in the treatment of these infections, and therefore telithromycin should be used with caution until further experience of emergence of resistance has been gained, especially in areas with a high prevalence of resistant pneumococci.
Slovenian: Toda klinične izkušnje s telitromicinom za zdravljenje teh okužb so še vedno skromne, zato je potrebno telitromicin uporabljati previdno dokler ne pridobimo nadaljnjih izkušenj v povezavi z odpornostjo bakterij, zlasti na področjih z visoko prevalenco odpornih pnevmokokov.